Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modulation of CD4 by suramin

P D Allen1, D H Johnston, M G Macey

  • 1Department of Surgery, Royal London Hospital, UK.

Clinical and Experimental Immunology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Management of Relapsed and Refractory Acute Myeloid Leukaemia in Adults.

Leukemia & lymphoma·2016
Same author

Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of Technique.

Leukemia & lymphoma·2016
Same author

A Pilot Study Using Intravenous Immunoglobulin for the Prevention of Infection During Remission Induction in Acute Leukaemia.

Leukemia & lymphoma·2016
Same author

Editorial.

Hematology (Amsterdam, Netherlands)·2016
Same author

Non-inpatient Treatment of Febrile Episodes in Patients with Hematological Malignancy.

Hematology (Amsterdam, Netherlands)·2016
Same author

Clinical Regression and Remission of Primary Refractory Angiocentric Lymphoma Following Autologous Tumour Peptide Antigen-charged Dendritic Cells After High-dose Chemotherapy and Autologous Stem Cell Rescue.

Hematology (Amsterdam, Netherlands)·2016

Suramin, an anti-cancer agent, significantly reduces T helper (CD4) cells in vitro. Its effects on other lymphocyte subsets and activation markers are less pronounced and reversible upon drug removal.

Area of Science:

  • Immunology
  • Pharmacology
  • Cancer Research

Background:

  • Suramin is a polysulfonated compound known to inhibit growth factors.
  • Renewed interest exists in suramin as a potential anti-cancer agent.
  • Its impact on lymphocyte populations and activation requires further investigation.

Purpose of the Study:

  • To investigate the effects of suramin on lymphocyte subset populations.
  • To examine suramin's impact on recombinant human interleukin-2 (rhIL-2)-induced lymphocyte activation in vitro.
  • To assess the reversibility and underlying mechanisms of suramin's modulatory effects.

Main Methods:

  • Flow cytometry was used to analyze lymphocyte subset populations (CD3, CD4, CD8, CD56).
  • The expression of activation antigens (CD25, CD71, HLA-DR) was assessed.

Related Experiment Videos

  • Suramin's effects were studied in the presence and absence of rhIL-2, and reversibility was tested.
  • The role of tyrosine kinase inhibition was explored using tyrphostin.

    • Main Results:

    • Suramin significantly decreased the percentage of CD4+ T helper cells in rhIL-2-treated lymphocytes.
    • Modest changes were observed in CD3, CD8, and CD56 expressing cells.
    • Suramin's effect on rhIL-2-induced activation antigen expression (CD25, CD71, HLA-DR) was equivocal.
    • The reduction in CD4 expression was reversible upon suramin removal and partially inhibited by a tyrosine kinase inhibitor.

    Conclusions:

    • Suramin exhibits a potent modulatory effect on CD4+ T helper cell populations in vitro.
    • The observed effects on CD4 expression are reversible and may involve tyrosine kinase pathways.
    • Further research is warranted to elucidate suramin's therapeutic potential in cancer, considering its immunomodulatory properties.